-
Je něco špatně v tomto záznamu ?
Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting
J. Cumova, L. Kovarova, A. Potacova, I. Buresova, F. Kryukov, M. Penka, J. Michalek, R. Hajek,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NS10207
MZ0
CEP - Centrální evidence projektů
NS10408
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Plný text - Článek
Zdroj
Zdroj
NLK
ProQuest Central
od 2001-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2001-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2001-01-01 do Před 1 rokem
- MeSH
- algoritmy MeSH
- imunomagnetická separace metody normy MeSH
- kostní dřeň patologie MeSH
- lidé MeSH
- metody MeSH
- mnohočetný myelom patologie MeSH
- software normy MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Plasma cells (PCs) enrichment from bone marrow samples of multiple myeloma (MM) patients is frequently performed by immunomagnetic separation (magnetic activated cell sorting, MACS) using anti-CD138 MicroBeads. The aim of our work was to find optimal strategy for immunomagnetic separation of PCs and determine optimal algorithm of separation techniques for samples with various percentage of neoplastic cells. From 2007 to 2008, selection of PCs using separation programs Possels and Posseld(2) was carried out on 234 bone marrow samples obtained from 208 MM patients. In 2008, an optimal algorithm for separation programs was introduced based on the analysis of the previous experiments. The Possels program is applicable for samples with >10% PCs in the mononuclear fraction, while the Posseld(2) program is used for samples with 5-10% PCs in the mononuclear fraction. Median purity of 92.6% for the positive fraction of cells (range 14.5-99.6%) and median recovery of 60.4% (range 25.7-99.5%) were obtained when the Possels program was applied (n = 45). A total of 80% (36/45) of processed samples had purity of >70%. Median purity for the positive fraction of 83.7% (range 14.3-99.7%) and median recovery of 14.3% (range 3.6-50.0%) were achieved using the Posseld(2) program (n = 99). A total of 68% (67/99) of processed samples reached >70% purity. This separation strategy enabled us to obtain sufficient amounts of highly purified PCs required for subsequent research purposes. The MACS method has been unsuccessful if the percentage of PCs in the initial sample was <5%. These samples were processed by fluorescence activated cell sorting (FACS).
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026170
- 003
- CZ-PrNML
- 005
- 20141219115132.0
- 007
- ta
- 008
- 120817e20100807xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12185-010-0651-4 $2 doi
- 035 __
- $a (PubMed)20694533
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Čumová, Jana $7 xx0122080 $u University Research Centre, Faculty of Medicine, Babak Research Institute, Masaryk University, Brno, Czech Republic. jazze@centrum.cz
- 245 10
- $a Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting / $c J. Cumova, L. Kovarova, A. Potacova, I. Buresova, F. Kryukov, M. Penka, J. Michalek, R. Hajek,
- 520 9_
- $a Plasma cells (PCs) enrichment from bone marrow samples of multiple myeloma (MM) patients is frequently performed by immunomagnetic separation (magnetic activated cell sorting, MACS) using anti-CD138 MicroBeads. The aim of our work was to find optimal strategy for immunomagnetic separation of PCs and determine optimal algorithm of separation techniques for samples with various percentage of neoplastic cells. From 2007 to 2008, selection of PCs using separation programs Possels and Posseld(2) was carried out on 234 bone marrow samples obtained from 208 MM patients. In 2008, an optimal algorithm for separation programs was introduced based on the analysis of the previous experiments. The Possels program is applicable for samples with >10% PCs in the mononuclear fraction, while the Posseld(2) program is used for samples with 5-10% PCs in the mononuclear fraction. Median purity of 92.6% for the positive fraction of cells (range 14.5-99.6%) and median recovery of 60.4% (range 25.7-99.5%) were obtained when the Possels program was applied (n = 45). A total of 80% (36/45) of processed samples had purity of >70%. Median purity for the positive fraction of 83.7% (range 14.3-99.7%) and median recovery of 14.3% (range 3.6-50.0%) were achieved using the Posseld(2) program (n = 99). A total of 68% (67/99) of processed samples reached >70% purity. This separation strategy enabled us to obtain sufficient amounts of highly purified PCs required for subsequent research purposes. The MACS method has been unsuccessful if the percentage of PCs in the initial sample was <5%. These samples were processed by fluorescence activated cell sorting (FACS).
- 650 _2
- $a algoritmy $7 D000465
- 650 _2
- $a kostní dřeň $x patologie $7 D001853
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunomagnetická separace $x metody $x normy $7 D018189
- 650 _2
- $a metody $7 D008722
- 650 _2
- $a mnohočetný myelom $x patologie $7 D009101
- 650 _2
- $a software $x normy $7 D012984
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kovářová, L
- 700 1_
- $a Potacová, A
- 700 1_
- $a Burešová, I
- 700 1_
- $a Kryukov, F
- 700 1_
- $a Penka, M
- 700 1_
- $a Michálek, J
- 700 1_
- $a Hájek, R
- 773 0_
- $w MED00002329 $t International journal of hematology $x 1865-3774 $g Roč. 92, č. 2 (20100807), s. 314-319
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20694533 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20141219115244 $b ABA008
- 999 __
- $a ok $b bmc $g 948212 $s 783516
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 92 $c 2 $d 314-319 $e 20100807 $i 1865-3774 $m International journal of hematology $n Int J Hematol $x MED00002329
- GRA __
- $a NS10207 $p MZ0
- GRA __
- $a NS10408 $p MZ0
- LZP __
- $a Pubmed-20120817/10/04